Alembic Pharmaceuticals shares plunged 8.02% to ₹721.25 on the National Stock Exchange (NSE) on May 18, 2026, shedding ₹62.85 from a previous close of ₹784.10. The stock was trading at ₹721.25, down 8.02% from its previous session's close of ₹784.10 as of 2:45 PM. The benchmark NSE Nifty50 was trading at 23,593.20 levels, down by 50.30 points or 0.21%. On a year-to-date basis, the stock has declined marginally by around 7% compared to a 9.5% fall in the Nifty50. The stock currently trades at ₹784.70, down 29.17% from its 52-week high of ₹1,107.80, reflecting sustained investor concerns about the underlying business trajectory.
As reported by Business Standard, Alembic Pharmaceuticals reported a 29% year-on-year rise in consolidated net profit to ₹202.70 crore compared to ₹156.89 crore in the year-ago period. However, the company's revenue for the quarter increased 4.4% to ₹1,847.72 crore as against ₹1,769.64 crore in the year-ago period. The earnings before interest, tax, depreciation, and amortisation (Ebitda) declined 29% Y-o-Y to ₹230 crore from ₹320 crore, with Ebitda margin narrowing to 12.3% from 15.4% in Q4FY25. The company's profit before tax came in at ₹119 crore, registering a decline of around 27% sequentially from ₹162 crore in Q3 FY6 and nearly 38% year-on-year from ₹192 crore in Q4 FY5. Despite lower operating profitability, net profit surged to ₹202.70 crore in Q4 FY6, compared to ₹132 crore in Q3 FY6 and ₹156.89 crore in Q4 FY5, representing a strong growth of approximately 53% quarter-on-quarter and nearly 29% year-on-year. The earnings per share (EPS) also improved significantly to ₹10.31 from ₹6.76 in the previous quarter. The most striking anomaly emerged in the tax line, with the company reporting a tax credit of ₹82.91 crore, resulting in a negative effective tax rate of 69.90%—a dramatic reversal from the normalised 18-19% tax rates observed in previous quarters. Stripping out this one-time benefit, the company's normalised profit after tax would have been approximately ₹95 crores, revealing that core profitability actually contracted by nearly 30%.
The market reaction was primarily driven by the company's performance missing analyst estimates across key metrics. Motilal Oswal had estimated Q4FY26 revenue of ₹1,890 crore, EBITDA of ₹320 crore, and adjusted PAT of ₹200 crore, while actual performance came in at revenue of ₹1,847.72 crore (a 2% miss), EBITDA of ₹230 crore (a 29% miss), and adjusted PAT of ₹120 crore (a 43% miss). A 43% PAT miss is not a rounding error and reflects a fundamental divergence between the cost trajectory and what analysts were modelling. The primary driver was R&D expenditure, which increased 31.25% year-on-year to ₹210 crore against ₹160 crore in Q4FY25, with management guiding this to continue at ₹750-800 crore for FY27, representing approximately 9% of expected revenues. Higher R&D, combined with elevated other operational costs, drove EBITDA margin contraction of 310 basis points year-on-year to 12.3% despite gross margin expansion of 120 basis points to 71.2%. Total expenses for Q4FY26 rose to ₹1,730.94 crore from ₹1,591.22 crore, producing the operating deleverage that crushed the margin. Motilal Oswal responded by cutting FY27 and FY28 earnings estimates by 12% and 6% respectively while maintaining its Neutral rating with a target price of ₹725.
According to Business Standard, the company's India-branded business grew 4% Y-o-Y to ₹568 crore during the quarter, with encouraging performance in gynaecology, gastrology, ophthalmology and animal healthcare segments. The international business grew 11% Y-o-Y to ₹564 crore, led by the US formulations segment, with the company launching six products in the US market during the quarter. Revenue from the ex-US generics business stood at ₹369 crore, while the company received four ANDA approvals during the quarter. The API business reported 2% Y-o-Y growth to ₹347 crore during the quarter. However, operational efficiency metrics paint a concerning picture, with the company's return on equity averaging just 11.80% over recent periods—significantly below the industry benchmark of 15-16% for quality pharmaceutical companies. The five-year EBIT growth rate of negative 8.78% underscores a troubling long-term trend of declining operating profitability. Operating profit margin declined to 12% in Q4 FY26 from 16% in the previous quarter, mainly due to higher operating expenses. The specialty segment faced challenges through FY26, with US sales growth being moderate at 7% year-on-year in constant currency terms despite a healthy pace of launches, indicating that new product approvals are not translating to proportionate revenue likely due to pricing pressure and competitive dynamics in the US generics market. The one bright spot was the commercial launch of Pivya — Alembic's entry into branded pharmaceuticals in the US — which marks a strategic shift toward higher-margin branded products, though Motilal Oswal noted that the launch is recent and prescription uptake needs monitoring.
Despite the earnings cuts, Motilal Oswal maintained a constructive medium-term outlook, projecting EBITDA and PAT CAGR of 21% and 26% respectively over FY26-28. Management guided FY27 US business growth of 10-15%, ROW business growth of over 15%, API business growth of approximately 10%, and India business growth in line with market — implying consolidated low double-digit revenue growth. EBITDA margin improvement is expected in FY27, with management reiterating an aspiration to reach approximately 20% EBITDA margins within two to three years from the current 12.3%. The brokerage's Neutral rating at ₹725 — effectively at the current price — reflects its view that even after the earnings cut, the stock's current valuation at 22.49x trailing earnings adequately prices in the upside from the US branded ramp and margin recovery. There is no margin of safety for a Buy call, and no deterioration severe enough for a Sell — leaving the stock in a holding pattern until the Pivya prescription ramp and Q1FY27 margin trajectory provide clearer signals.
